Loading...
•
Jun 30, 2024
Cytokinetics Q2 2024 Earnings Report
Cytokinetics reported financial results for Q2 2024 and provided a management update.
Key Takeaways
Cytokinetics reported a net loss of $143.3 million for the second quarter of 2024. The company had $1.4 billion in cash, cash equivalents and investments as of June 30, 2024.
Held Type B meeting with FDA regarding risk mitigation strategies for aficamten.
Initiated rolling NDA submission for aficamten.
FDA cleared protocol amendment for FOREST-HCM, reducing echocardiographic monitoring frequency.
Cash, cash equivalents, and investments totaled ~$1.4 billion as of June 30, 2024.
Forward Guidance
The company updated its full year 2024 financial guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...